The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients' Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers.

导出 OA

翻译打印收藏纠错

作者： Soo Young,Jun ^[1] ; Hyang Ran,Yoon ^[2] ; Ji-Yong,Yoon ^[3] ; Su-Jin,Jeon ^[4] ; Jeong-Ju,Lee ^[1] ; Debasish,Halder ^[2] ; Jin-Man,Kim ^[1] ; Nam-Soon,Kim ^[2]

作者单位： Medical Genomics Research Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon 34141, Korea. ^[1] Rare-Disease Research Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon 34141, Korea. ^[2] Department of Functional Genomics, University of Science & Technology, Daejeon 34113, Korea. ^[3] Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon 34141, Korea. ^[4] Department of Pathology, Chungnam National University College of Medicine, Chungnam National University Hospital, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea. ^[5]

关键词 Kaplan–Meier analysis cluster of differentiation 44 (CD44)hepatocellular carcinomas (HCCs)human TOR signaling regulator (TIPRL)intrahepatic carcinomas (iCCA)liver cancer microtubule-associated light chain 3 (LC3)prominin-1 (CD133)receiver-operating characteristic (ROC) curve uni-/multi-Cox analyses

DOI 10.3390/cancers13122925

PMID 34208132

发布时间 2024-04-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交